Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × umbralisib × Clear all

NCT03919175 2026-02-27

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Terminated

18 enrolled 11 charts

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT04508647 2024-03-21

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Phase 2 Completed

4 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03364231 2023-06-23

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Phase 2 Completed

21 enrolled 14 charts

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT04635683 2022-09-30

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02793583 2022-07-21

UNITY-NHL

Phase 2/3 Terminated

710 enrolled 1 FDA

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell